United Kingdom: Scientists have developed a new technique for diagnosing Parkinson’s disease before symptoms show up, speeding up the hunt for a cure.
Parkinson’s is difficult to diagnose since there is no specific test for the condition. Symptoms vary, and several other illnesses have similar symptoms, which means the condition can often be misdiagnosed.
The new study published in the Lancet Neurology journal has come up with a way to identify the buildup of abnormal proteins associated with the disease long before symptoms show.
The research method known as the alpha-synuclein seed amplification assay (alphaSyn-SAA) can accurately identify people who are at risk of developing the disease. The findings thus pave the way for early detection, diagnosis, and treatment of Parkinson’s.
Prof. Andrew Siderowf, of the University of Pennsylvania, a co-lead author of the study, commented that “identifying an effective biomarker for Parkinson’s disease pathology could have profound implications for the way we treat the condition, potentially making it possible to diagnose people earlier, identify the best treatments for different subsets of patients, and speed up clinical trials.”
Parkinson’s is caused by the buildup of abnormal proteins known as alpha-synuclein (alphaSyn) throughout the brain and nervous system. This buildup is thought to take place years before physical symptoms such as tremors, slowness of movement, or stiff muscles start to emerge.
The study involved 1,123 participants, making it one of the largest so far to assess the usefulness of the alphaSyn-SAA technique. The research team confirmed that the technique could accurately detect people with Parkinson’s and also suggested it could identify individuals at risk and those with early, non-motor symptoms before diagnosis.
However, the researchers cautioned that further, longer-term studies with larger sample sizes would be needed to fully assess the usefulness of the alphaSyn-SAA technique.